Lau, David CW;
Batterham, Rachel L;
le Roux, Carel W;
(2022)
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
Expert Review of Clinical Pharmacology
, 15
(3)
pp. 251-268.
10.1080/17512433.2022.2070473.
Preview |
PDF
Pharmacological profile of once weekly injectable semaglutide for chronic weight management.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction: The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly injectable semaglutide 2.4 mg, as an adjunct to a calorie-controlled diet and increased physical activity, for chronic weight management provides health-care practitioners with an additional option when prescribing weight-loss medication. Areas covered: We describe the chemistry, mechanism of action, and pharmacological properties of semaglutide (a glucagon-like peptide 1 receptor agonist [GLP-1 RA]) and discuss clinical data and considerations for using once-weekly subcutaneous semaglutide 2.4 mg as treatment for overweight and obesity among patients with and without type 2 diabetes (T2D). Expert opinion: Once-weekly subcutaneous semaglutide 2.4 mg is the most efficacious medication approved for chronic weight management among patients with overweight and obesity, with and without T2D, and is the first drug to induce sustained double-digit reductions in percentage body weight over 1- to 2-year treatment periods. It demonstrates a similar safety and tolerability profile to other GLP-1 RAs. Semaglutide 2.4 mg treatment could dramatically improve clinical approaches to weight management, but the relatively high cost might prevent patients accessing treatment. Further research exploring the cost-effectiveness of subcutaneous semaglutide 2.4 mg is required.
Type: | Article |
---|---|
Title: | Pharmacological profile of once-weekly injectable semaglutide for chronic weight management |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1080/17512433.2022.2070473 |
Publisher version: | https://doi.org/10.1080/17512433.2022.2070473 |
Language: | English |
Additional information: | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
Keywords: | Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Anti-obesity medication, diabetes, GLP-1 RAs, obesity, semaglutide 2, 4 mg, weight management, GLUCAGON-LIKE PEPTIDE-1, DOUBLE-BLIND, UPDATED METAANALYSIS, PRACTICE GUIDELINES, AMERICAN-COLLEGE, DOUBLE-DUMMY, BODY-WEIGHT, PHASE 3A, 2.4 MG, OBESITY |
UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Experimental and Translational Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
URI: | https://discovery.ucl.ac.uk/id/eprint/10151895 |
Archive Staff Only
View Item |